Every Cure’s drug repurposing strategy isn't what you think, and it could change rare disease treatment

Launch of the drug-repurposing non-profit Every Cure by David Fajgenbaum challenged traditional research models by prioritizing repurposing existing drugs to accelerate treatment discovery. This underscores a shift toward mission-driven, translational approaches and potential partnership opportunities with biotech players, but carries minimal near-term market impact.

Analysis

Launch of the drug-repurposing non-profit Every Cure by David Fajgenbaum challenged traditional research models by prioritizing repurposing existing drugs to accelerate treatment discovery. This underscores a shift toward mission-driven, translational approaches and potential partnership opportunities with biotech players, but carries minimal near-term market impact.